(Treatment for tumors)
Chemical formula: Cl2H6N2Pt
Molecular weight: 300.0474
Cisplatin or cis-diamminedichloroplatinum(II) (CDDP) is a platinum -based chemotherapy drug used to treat various types of cancers, including sarcomas , some carcinomas (e.g. small cell lung cancer and ovarian cancer ), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Structure as following:
Cisplatin is chemotherapy that is given as a treatment for some types of cancer. It is most commonly used to treat testicular , bladder , lung , gullet (oesophagus), stomach , and ovarian cancers.
Cisplatin also is used to treat certain types of head and neck cancer, cervical carcinoma, lung cancer, neurologic cancers, and a wide variety of other cancers. Talk to your doctor about the possible risks of using this drug for your condition.
Mode of action
Cisplatin acts by crosslinking DNA in various different ways, making it impossible for rapidly dividing cells to duplicate their DNA for mitosis . The damaged DNA sets off DNA repair mechanisms, which activate apoptosis when repair proves impossible. The trans isomer does not have this pharmacological effect.
Most notable among the DNA changes are the intrastrand Gp G adducts which form nearly 90% of the adducts. Other adducts include inter-strand crosslinks and nonfunctional adducts that have been postulated to contribute to its activity. Interaction with cellular proteins has also been advanced as a mechanism of interfering with mitosis, although this is probably not its main action.
Cisplatin has a number of side-effects that can limit its use:
- Nephrotoxicity (kidney damage) is a major concern when cisplatin is prescribed as a chemotherapy agent. The dose therefore has to be tailored to the patient's creatinine clearance (a measure of renal function ), and adequate hydration and diuresis is used to prevent renal damage.
- Neurotoxicity (nerve damage) can be anticipated by performing nerve conduction studies before and after treatment.
- Nausea and vomiting . Cisplatin is one of the most emetogenic chemotherapy agents, but this is managed with prophylactic antiemetics (e.g. ondansetron , granisetron , etc.) in combination with corticosteroids .
- Ototoxicity (hearing loss)
- Hair loss.
As a compound cisplatin was first described by M. Peyrone in 1845. The structure was elucidated by Alfred Werner in 1893. It was rediscovered in the 1960s by Rosenberg et al , who discovered that electrolysis products from a platinum electrode inhibited mitosis in Escherichia coli ( E. coli ) bacteria. The bacteria grow to 300 times their normal length but cell division fails.
In the 1970s, a series of experiments were conducted at Michigan State University to test the effects the cis-diamminedichloroplatinum(II), along with other platinum coordination complexes, on sarcomas artificially implanted in rats . This study found that cis-diamminedichloroplatinum(II) was the most effective out of this group, which started the medicinal career of cisplatin.
Approved for clinical use by the American Food and Drug Administration ( FDA ) in 1978, it revolutionized the treatment of certain cancers. Detailed studies on its molecular mechanism of action, using a variety of spectrocopic methods including X-ray, NMR and other physico-chemical methods, revealed its ability to form irreversible crosslinks with bases in DNA.